International Journal of Antimicrobial Agents
Volume 36, Issue 6 , Pages 485-490, December 2010

Intravesical gentamicin for recurrent urinary tract infection in patients with intermittent bladder catheterisation

  • C. van Nieuwkoop

      Affiliations

    • Department of Infectious Diseases, Leiden University Medical Center, C5-P, P.O. Box 9600, 2300 RC Leiden, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 71 526 2613; fax: +31 71 526 6758.
  • ,
  • P.L. den Exter

      Affiliations

    • Department of Infectious Diseases, Leiden University Medical Center, C5-P, P.O. Box 9600, 2300 RC Leiden, The Netherlands
  • ,
  • H.W. Elzevier

      Affiliations

    • Department of Urology, Leiden University Medical Center, The Netherlands
  • ,
  • J. den Hartigh

      Affiliations

    • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, The Netherlands
  • ,
  • J.T. van Dissel

      Affiliations

    • Department of Infectious Diseases, Leiden University Medical Center, C5-P, P.O. Box 9600, 2300 RC Leiden, The Netherlands

published online 28 June 2010.

Abstract 

Clean intermittent catheterisation (CIC) of the bladder is used to imitate normal bladder emptying in patients with bladder dysfunction. CIC is associated with urinary tract infection (UTI) that may be difficult to treat in the case of antimicrobial resistance. The aim of this study was to establish the effect and safety of intravesical gentamicin treatment in such settings. In 2009, intravesical gentamicin treatment was started in selected patients. Here we describe our experience with two patients treated until March 2010. Two patients using CIC suffering recurrent UTI with multiresistant Escherichia coli were treated with daily administration of 80mg intravesical gentamicin. On treatment they appeared asymptomatic. During 8- and 9-month follow-up they were free of UTI, urine cultures were negative and there were no side effects. A systematic review was conducted through searches of PubMed and other databases. Clinical trials that met the eligibility criteria and displayed the efficacy or safety of intravesical aminoglycoside treatment in patients using CIC were studied. Study selection was performed by two independent reviewers. Eight studies were included for review. Owing to study heterogeneity, a meta-analysis could not be performed. Of four controlled studies using neomycin or kanamycin, two demonstrated a significant reduction in bacteriuria, whilst two other trials did not. One case series on neomycin/polymyxin showed that the majority of patients still developed bacteriuria. Three case series using gentamicin all pointed towards a significant reduction in bacteriuria and UTIs. There were no clinically relevant side effects reported but follow-up in all studies was limited. Although data are limited, intravesical treatment with gentamicin might be a reasonable treatment option in selected patients practicing CIC who suffer recurrent UTIs with highly resistant microorganisms.

Keywords: Urinary tract infection, Intermittent bladder catheterisation, Intravesical gentamicin, Systematic review

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0924-8579(10)00223-2

doi:10.1016/j.ijantimicag.2010.05.005

International Journal of Antimicrobial Agents
Volume 36, Issue 6 , Pages 485-490, December 2010